Author Archives: admin


Stem Cell Clinic > Articles by: admin

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Stell Cell Research

WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis’ common stock to nine newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Read the original post:
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Embryonic Stem Cells

DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

More:
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

By Embryonic Stem Cells

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date”), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025.

Here is the original post:
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression

By Platelet Rich Plasma Injections

- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 (liafensine) in treatment-resistant depression (TRD) -

Read more from the original source:
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic…

By Platelet Rich Plasma Injections

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –

See more here:
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic...

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented…

By Platelet Rich Plasma Injections

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the company will host a webcast conference call at 8:00 a.m., ET, on Thursday, June 12, 2025, to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress in Milan, Italy.

Read more from the original source:
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented...

Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting

By Platelet Rich Plasma Injections

Data show SPR301 lowered ?-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with favorable safety

Read more from the original source:
Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Platelet Rich Plasma Injections

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 79,200 shares of common stock to five (5) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

More here:
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

←